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MLL-fusion-driven leukemia requires SETD2 to
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MLL-fusions represent a large group of leukemia drivers, whose diversity originates from the
vast molecular heterogeneity of C-terminal fusion partners of MLL. While studies of selected
MLL-fusions have revealed critical molecular pathways, unifying mechanisms across all
MLL-fusions remain poorly understood. We present the ﬁrst comprehensive survey of
protein–protein interactions of seven distantly related MLL-fusion proteins. Functional
investigation of 128 conserved MLL-fusion-interactors identiﬁes a speciﬁc role for the lysine
methyltransferase SETD2 in MLL-leukemia. SETD2 loss causes growth arrest and
differentiation of AML cells, and leads to increased DNA damage. In addition to its role in
H3K36 tri-methylation, SETD2 is required to maintain high H3K79 di-methylation and
MLL-AF9-binding to critical target genes, such as Hoxa9. SETD2 loss synergizes with
pharmacologic inhibition of the H3K79 methyltransferase DOT1L to induce DNA damage,
growth arrest, differentiation, and apoptosis. These results uncover a dependency for SETD2
during MLL-leukemogenesis, revealing a novel actionable vulnerability in this disease.
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Leukemia-associated fusion proteins serve as a paradigm formodern cancer research, as the molecular machineries thatprovide their functional cellular context have emerged as
amenable to targeted molecular approaches1,2. Families of related
leukemia fusion proteins that share genomic and biological
properties represent unique opportunities to study how the
combination of distinct functional protein modules can drive
oncogenic transformation. The largest family of “multi-partner
translocations” in acute leukemia comprises fusions involving the
product of the KMT2A (MLL) gene. MLL-fusion proteins are
found in acute lymphoblastic leukemia (ALL) and acute myeloid
leukemia (AML) and are often associated with adverse prognosis,
particularly in pediatric patients3. Expression of MLL-fusions
enhances proliferation and blocks myeloid differentiation of
hematopoietic progenitor cells, leading to their pathological
accumulation. In line, many MLL-fusions can act as potent
oncogenes in cell line models and animal models of leukemia4.
In leukemia, the MLL N-terminus takes part in >120 different
translocations, resulting in the generation of MLL-fusion proteins
encompassing more than 75 different partner genes5. It has
therefore been proposed that the oncogenic activity of MLL-
fusion proteins depends on chromatin targeting functions exerted
by the MLL N-terminus in combination with other functional
properties encoded by the fusion partners6. Several regions in the
MLL N-terminus are critical for the activity of MLL-fusions. For
instance, the CxxC-domain is essential for DNA binding of MLL-
fusion proteins7. Furthermore, the MLL-interacting protein
Menin links MLL-fusion proteins with LEDGF, and the
H3K36me3-binding PWWP domain of LEDGF is critical for the
function of MLL-fusions8. In fact, a direct fusion of the LEDGF
PWWP domain to MLL was able to replace Menin altogether9.
Numerous studies have established strong links between the
molecular function of the fusion partner and the mechanistic
basis of oncogenic transformation in MLL-fusion-induced leu-
kemogenesis4. Pioneering biochemical experiments have shown
that several fusion partners of MLL, such as AF4, AF9, and ENL
are members of the DOT1L complex (DotCom) and the super-
elongation complex (SEC)10–13, which are both involved in
transcriptional control. As the SEC can regulate the transcrip-
tional activity of RNA polymerase II, it was hypothesized that
these MLL-fusions induce aberrant regulation of transcriptional
elongation on MLL-target genes14.
A large number of factors was shown to inﬂuence the onco-
genic properties of MLL-fusions, including signaling
proteins15–17, epigenetic modulators18–21, and transcription fac-
tors22–24, as well as the wild-type MLL protein25. However, it is
unclear whether these molecular mechanisms pertain to the entire
family of MLL-fusions or if they speciﬁcally affect the leukemo-
genicity of isolated MLL-fusion proteins. In fact, speciﬁc mole-
cular mechanisms of oncogenic transformation were postulated
to prevail for selected MLL-fusions. For instance, inhibition of the
arginine methyltransferase PRMT1 was shown to reduce the
leukemic potential of several oncogenic fusion proteins, including
MLL-EEN and MLL-GAS7, but not MLL-AF9, MLL-AF10, or
MLL-ENL26,27. Furthermore, the enzymatic activity of CBP was
shown to be required for leukemogenic activity of fusions of MLL
with the histone acetyltransferase CREBBP28,29. Finally, dimer-
ization might play an important role in nuclear translocation and
oncogenic transformation in fusions of MLL to the cytoplasmic
partner proteins GAS7 and AF1p, yet the underlying molecular
mechanism is unclear30,31.
Here, we set out to survey the molecular composition of a
diverse subset of distantly related MLL-fusion protein complexes
to characterize their unique and common properties, and to
reveal possible actionable vulnerabilities that are based on speciﬁc
molecular mechanisms shared by MLL-fusions. We identify the
methyltransferase SETD2 as an interactor of all MLL-fusion
proteins. shRNA-mediated and CRISPR/Cas9-mediated loss of
SETD2 leads to growth arrest and differentiation of MLL-fusion-
expressing cells in vitro and in vivo. Moreover, we show that loss
of SETD2 is associated with increased DNA damage. SETD2 loss
disrupts a H3K36me3-H3K79me2 signature on MLL-target genes
and sensitizes MLL-AML cells to pharmacologic inhibition of the
known MLL-fusion protein effector DOT1L. In summary, we
describe a novel dependency for SETD2 in the initiation and
maintenance of MLL-rearranged leukemia, highlighting a novel
vulnerability in this disease.
Results
Functional proteomic survey of MLL-fusion proteins. Reason-
ing that critical effectors might be enriched among the physical
interaction partners of distantly related MLL-fusion proteins, we
undertook an unbiased survey of the protein–protein interactions
of MLL-fusion proteins in leukemia cells. Using FRT/Flp-medi-
ated locus-speciﬁc cassette exchange, we generated isogenic Jurkat
leukemia cell lines allowing for Doxycycline (Dox)-inducible,
single-copy expression of afﬁnity-tagged variants of seven MLL-
fusions that were previously proposed to employ different
molecular mechanisms of oncogenic transformation (MLL-AF1p,
MLL-AF4, MLL-AF9, MLL-CBP, MLL-EEN, MLL-ENL, MLL-
GAS7, Fig. 1a, b and Supplementary Fig. 1a-c). Subcellular frac-
tionation revealed that all selected MLL-fusion proteins localized
to the nucleus (Supplementary Fig. 1d) and were capable of
inducing expression of the MLL-fusion-target genes HOXA5,
HOXA9, HOXA10, and MEIS1 (Fig. 1c).
Protein complexes around MLL-fusion proteins were puriﬁed
from nuclear lysates of cell lines expressing seven distinct MLL-
fusions (Fig. 1d and Supplementary Fig. 2a). Puriﬁcations were
analyzed by LC-MS/MS using both one-dimensional and two-
dimensional gel-free proteomic approaches, recovering 4600
proteins in total, engaging in 15,094 putative interactions
(Fig. 1e and Supplementary Fig. 2b)32–34. p-value-based
ﬁltering for the 300 most signiﬁcant interactions per MLL-
fusion resulted in a network of 960 high-conﬁdence cellular
proteins (Supplementary Fig. 2b). Validation of the network
conﬁrmed previously reported interactions of MLL-fusions
with protein complexes important for transcriptional control
and epigenetic regulation, including the PAF complex, the SWI/
SNF complex, and Polycomb Repressor Complex 1 (Supple-
mentary Fig. 2c)12,35–37. The network also revealed abundant
unique interaction partners of all MLL-fusion proteins,
indicating that distinct MLL-fusions can engage speciﬁc
molecular pathways. 406 proteins in the network (42.3%) co-
puriﬁed with more than one MLL-fusion protein, while 128
proteins (13.3%) interacted with at least ﬁve of the seven MLL-
fusions (Supplementary Fig. 2b), indicating a strong degree of
topological conservation within the MLL-interaction network.
Further analysis of the 128 conserved partners of MLL-fusion
proteins revealed six distinct protein communities (p < 0.01;
Supplementary Table 1), whose annotation retrieved molecular
functions that are highly relevant to the biology of MLL-fusion
proteins, including chromatin remodeling, transcriptional
elongation, and hematopoiesis (Fig. 1e). Interestingly, protein
families that had not been reported to interact with MLL-fusion
proteins before were also identiﬁed, such as factors involved in
DNA-repair, RNA splicing, and RNA transport.
In summary, our comprehensive analysis and validation of the
cellular interaction networks shows that distinct MLL-fusion
proteins engage in a high number of direct, as well as indirect
protein–protein interactions. Structurally different MLL-fusion
proteins share 128 conserved interaction partners, which are
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enriched in six functional communities that are highly relevant
for the biology of MLL-fusion proteins.
shRNA screen identiﬁes SETD2 as an effector of MLL-fusions.
As our primary validation reduced the number of potential cri-
tical effectors in the network of MLL-fusion protein-interactors
from 960 to 128, we next aimed to further narrow down the circle
of candidate proteins using sequential functional genomic
approaches (Fig. 2a). To systematically investigate the functional
contribution of the conserved 128 MLL-interaction partners to
MLL-fusion-dependent leukemia, we devised a shRNA screen in
the human MLL-AF9-expressing AML cell line MOLM-13. In the
system used by us, transcriptional coupling of ﬂuorescent reporter
proteins to shRNA expression upon Dox-induction allows for
dynamic monitoring of competing growth kinetics in mixed cell
populations expressing experimental shRNAs (GFP) vs. non-
targeting control shRNAs (shRen.713, dsRed, Fig. 2b). While
expression of a control shRNA did not differentially affect cell
proliferation in mixed populations over time, strong shRNA-
induced negative selection of GFP-positive cells was observed
upon targeting of MEN1, an interaction partner of all seven
investigated MLL-fusion proteins with a well-known function in
MLL-fusion-induced leukemogenesis38 (Fig. 2b, bottom). We
used this setup to systematically test the effects of 128 shRNA-
pools targeting conserved MLL-fusion interaction partners on
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Fig. 1 Functional proteomic survey of the MLL-fusion interactome. Cells expressing Strep-HA (SH)-tagged MLL-AF9 or mock-transfected cells were treated
with Dox for the indicated time points and transgene expression was monitored by immunoblotting (a) and qPCR (b) (means ± s.d. n= 3). c SH-MLL-AF9-
expressing cells were treated with Dox for 24 h and the expression of indicated MLL-target genes was measured by qPCR (mean ± s.d. n= 3). d Schematic
illustration of the strategy of afﬁnity puriﬁcation of protein complexes associated with MLL-fusion proteins from nuclear lysates of cell lines expressing
afﬁnity-tagged MLL-fusion proteins. e Gene ontology (GO) enrichment of six distinct protein communities among the core 128 interactors shared by at
least 5 of 7 MLL-fusion proteins
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AML cell growth. Relative depletion of all shRNA-pools was
normalized to a negative-control shRNA (shRen.713) and to a
strong growth inhibitory positive-control shRNA (shMyb.670)22.
As the read-out of this screen is inhibition of proliferation, we
would expect that essential genes would be enriched among the
strongest hits. Indeed, scoring of shRNA-induced effects upon
knockdown of all 128 MLL-fusion interactors revealed a strong
positive correlation between growth inhibition and reported gene
essentiality (Fig. 2c)39–42. However, as we intended to identify
proteins with MLL-fusion-speciﬁc roles in the network, we rea-
soned that their loss-of-function might preferably affect the via-
bility of MLL-fusion-expressing leukemia cells. Thus, we re-
screened the 40 candidate genes with the highest conﬁdence in
MLL-AF9-expressing MOLM-13 cells and in the MLL-wild-type
leukemia cell lines K562 and HL-60. As expected, knockdown of
MLL-interactors with known essential functions, such as RFC1,
SF3A3, or CCT3, led to growth inhibition in both MLL-fusion
cells and MLL-wild-type leukemia cells (Fig. 2d). In contrast,
depletion of the known MLL-interaction partner MEN1 selec-
tively inhibited growth of MLL-fusion cells while sparing MLL-
wild-type cells, proving the validity of the chosen strategy.
Knockdown of the gene encoding the H3K36me3-speciﬁc
methyltransferase SETD2 showed a strong bias towards inhibition
of proliferation of MLL-fusion-expressing cells, while causing
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Fig. 2 shRNA screen identiﬁes SETD2 as a critical effector of MLL-fusions. a Schematic representation of the ﬁltering strategy. Afﬁnity puriﬁcation coupled
to mass spectrometry identiﬁed 960 candidate genes (top 300 interactors per bait, ranked by p-value) to interact with at least one of seven selected MLL-
fusion proteins. 128 proteins interacted with ≥5 of seven MLL-fusions. 40 candidate genes were screened in MLL-rearranged vs. MLL-wild-type cell lines.
Each square corresponds to 20 interactors. b Schematic outline of retroviral vectors and experimental design of the FACS-based negative selection RNAi
screen. Competitive proliferation assays were set up by mixing cells in a 50:50 ratio (experimental-GFP vs. control-dsRed) and cultivation in the presence
of Dox. The relative ratio of GFP-positive vs. dsRed-positive cells was monitored by ﬂow cytometry over 14 days. Bar graphs (bottom) represent the
performance of positive (shMEN1.1105) and negative (shRen.713) controls shown as percentage of GFP+ cells over time. c Summary of RNAi screening
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negligible cell depletion in K562 and HL-60 cells, suggesting an
MLL-fusion-speciﬁc function (Fig. 2d, Supplementary Fig. 3a).
SETD2 was one of 42 core proteins that interacted with all seven
MLL-fusions, as it co-puriﬁed with MLL-fusion proteins in all
afﬁnity-puriﬁcation experiments with signiﬁcant peptide coverage
(Supplementary Fig. 3b). Consistently, co-immunoprecipitation
experiments showed that this interaction involved the N-terminal
part of MLL, which is conserved in all MLL-fusion proteins studied,
and the C-terminus of SETD2, which encompasses all annotated
functional domains of the SETD2 protein (Supplementary Fig. 3c).
SETD2 expression was higher in AML samples than in normal
hematopoietic stem and progenitor cell types and mature myeloid
cells43 (Supplementary Fig. 3d). SETD2 expression was highest in
patients with 11q23 aberrations featuring MLL-translocations, as
compared to samples with normal karyotype AML or myelodys-
plastic syndrome (Supplementary Fig. 3e).
Thus, we identiﬁed the methyltransferase SETD2 as a selective
effector of MLL-AF9 AML cells through functional genomic investi-
gation of conserved interaction partners of MLL-fusion proteins.
SETD2 is essential for MLL-fusion-expressing cells. We next
aimed at validating the shRNA screen results at the level of
individual shRNAs. Expression of all six SETD2-targeting
shRNAs induced strong growth inhibition in MOLM-13 cells, in
line with signiﬁcant downregulation of SETD2mRNA (Fig. 3a, b).
As SETD2 is the only protein known to mediate tri-methylation
of H3K3644, we investigated the effect of SETD2 downregulation
on total cellular H3K36me3 levels. The three strongest SETD2-
targeting shRNAs caused near-complete clearance of global
H3K36me3 signals (Fig. 3c). Importantly, growth inhibition was
not generally associated with H3K36me3 loss, as we did not
observe changes in global H3K36me3 levels upon downregulation
of MLL and MYB, which strongly affected proliferation of MLL-
AF9 AML cells (Fig. 3c).
As our screening data indicate that SETD2 knockdown
selectively inhibits the proliferation of MLL-fusion-expressing
cells, we sought to extend this observation to a larger panel of
human leukemia cell lines. In addition to MOLM-13 cells also the
MLL-AF4-expressing cell lines MV4-11 and SEM showed
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Fig. 3 SETD2 is required for proliferation of MLL-leukemia cells. a Results of FACS-based competitive proliferation assay shown as the percentage of GFP-
positive MOLM-13 cells expressing individual SETD2-targeting shRNAs in the presence of Dox over 14 days. One representative experiment of four is
shown. b qPCR analysis of SETD2 mRNA levels in MOLM-13 cells expressing indicated shRNAs after 48 h of Dox treatment (mean ± s.d. n= 3). cWestern
blot analysis of H3K36me3 levels in MOLM-13 cells expressing indicated shRNAs after 72 h of Dox treatment. d Heatmap representation of competitive
proliferation assays performed in human cell lines harboring MLL rearrangements (left) vs. MLL-wild-type cells (right) expressing indicated shRNAs
targeting SETD2 as described in a. Representative results of two out of three experiments are shown. e Time course of GFP expression of primary human
AML cells from patients expressing MLL-AF9 and MLL-LASP1 fusion genes expressing indicated shRNAs (mean ± s.d. n= 3)
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signiﬁcant anti-proliferative responses and induction of apoptosis
upon SETD2 knockdown (Fig. 3d, left, and Supplementary
Fig. 4a-c). In contrast, SETD2 downregulation in the MLL-wild-
type cell lines HEL, HL-60, and KYO-1 only marginally affected
proliferation (Fig. 3d, right, Supplementary Fig. 4c). SETD2
knockdown resulted in a strong proliferative disadvantage in
primary human AML cells from patients expressing MLL-AF9
and MLL-LASP1 fusion genes (Fig. 3e).
Taken together, downregulation of SETD2 caused a strong
anti-proliferative response in primary human AML cells and
cell lines expressing various MLL-fusion genes, suggesting a
requirement for SETD2 in the oncogenic context of MLL-fusion
proteins.
MLL-target genes exhibit high H3K36me3 levels. To investigate
the relationship between SETD2 and MLL-fusions we proﬁled the
global distribution of the SETD2-dependent H3K36me3 mark in a
mouse AML cell line expressing MLL-AF9 and activated Nras
(G12D)22 using ChIP-Rx45. As expected, H3K36me3 was present
on gene bodies of expressed genes. We found that MLL-AF9 target
genes22 displayed signiﬁcantly higher H3K36me3 levels than non-
MLL-target genes (Fig. 4a, top). In line with previous data, MLL-
fusion target genes were also highly positive for the DOT1L-
dependent H3K79me2 mark21 (Fig. 4a, bottom), and the global
levels of H3K36me3 and H3K79me2 modiﬁcations showed a
strong positive correlation in mouse MLL-AF9/NrasG12D cells
(Fig. 4b). However, while only 42% of non-MLL-target genes were
highly positive for both marks, 76% of MLL-target genes displayed
a combined H3K36me3/H3K79me2-high signature (Fig. 4c, d, and
Supplementary Fig. 5). As MLL-fusion-binding was shown to
correlate with H3K79me2 on MLL-target genes21 and depend on
recognition of H3K36me3 marks9, these data suggest that the
SETD2-dependent H3K36me3 modiﬁcation is part of an epige-
netic signature that marks target genes of MLL-fusion proteins
together with H3K79me2.
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Loss of SETD2 induces myeloid differentiation and DNA
damage. Next we sought to characterize global changes in gene
expression upon SETD2 ablation. Dox-inducible knockdown of
Setd2 caused a strong growth disadvantage in mouse MLL-AF9/
NrasG12D cells (Fig. 5a, b, Supplementary Fig. 6a). Setd2
downregulation led to almost complete loss of cellular
H3K36me3 signals (Fig. 5c). RNA-seq analysis showed that 868
genes were differentially expressed upon Setd2 knockdown in
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MLL-AF9/NrasG12D AML cells. While 458 genes were upregu-
lated, 410 genes were downregulated in shSetd2-cells, (padj < 0.01,
Supplementary Fig. 6b). Consistent with a role of SETD2 in the
DNA damage response46, MLL-AF9/NrasG12D AML cells
expressing two different Setd2-targeting shRNAs showed upre-
gulation of DNA damage-associated gene expression (Supple-
mentary Fig. 6c). Indeed, Setd2 downregulation resulted in
signiﬁcantly higher levels of DNA damage in the absence of
genotoxic agents, as measured by alkaline comet assay and
phosphorylated histone H2AX (γ-H2AX, Supplementary Fig. 7a-
c). Knockdown of Setd2 led to induction of p21, reduced cell cycle
progression, and induction of apoptosis of MLL-AF9/NrasG12D
AML cells (Supplementary Fig 7c-e).
Gene Set Enrichment Analysis revealed that Setd2 down-
regulation induced gene expression programs associated with
myeloid differentiation (Fig. 5d). Indeed, Setd2-deﬁcient cells
displayed clear signs of terminal myeloid maturation, including
nuclear segmentation and increased granularity (Fig. 5e), as well
as downregulation of the progenitor marker c-Kit and upregula-
tion of the mature myeloid marker Mac-1 (Supplementary
Fig. 8a). Similarly, SETD2 downregulation in the human MLL-
AF4-expressing cell line MV4-11 and in MLL-AF9-expressing
MOLM-13 cells induced increased cell surface levels of the
differentiation marker CD36 together with macroscopic changes
characteristic of myeloid maturation (Supplementary Fig. 8b, c).
To test whether loss of SETD2 could overcome the MLL-AF9-
dependent differentiation block in myeloid progenitors in vivo, we
transplanted MLL-AF9/NrasG12D AML cells expressing Setd2-
targeting or control shRNAs into recipient mice. shRNA expression
was induced by Dox-administration and the immuno-phenotype of
the developing leukemia was analyzed by ﬂow cytometry (Fig. 5f).
Knockdown of Setd2 induced strong downregulation of c-Kit
concomitant with upregulation of Mac-1 in leukemic cells in vivo,
resulting in a signiﬁcant increase in disease latency (Fig. 5g, h and
Supplementary Fig. 8d). This is consistent with recent results
showing that knockout of Setd2 greatly increased the latency of
MLL-AF9-induced AML47. While most leukemia cells isolated from
moribund recipients of control AML cells showed robust shRNA
expression (as measured by GFP levels), shRNA-expressing cells
were strongly outcompeted by shRNA-negative cells in case of Setd2
knockdown in vivo (Supplementary Fig. 8e).
In summary, shRNA-mediated downregulation of SETD2
caused growth arrest, induction of apoptosis, and increased
DNA damage. Furthermore, SETD2 loss induced terminal
myeloid differentiation in MLL-fusion-expressing mouse and
human AML cells in vitro and in vivo, indicating that the MLL-
fusion-induced differentiation block is SETD2-dependent.
The SETD2 SET domain is required for AML growth. To
interrogate the translational potential of our ﬁndings, we next
500 1000 1500 2000 2500
AWS-SET-PostSET
PWWP
SRI
aa
SETD2
sgRNAs:
0
20
40
60
80
100
d2
d4
d6
d9
d11
%
 G
F
P
+
/m
C
he
rr
y+
 c
el
ls
Mouse MLL-AF9/NRasG12D - SpCas9
Rosa26 Myb.33 e5.1 e6.1 e8.1
a
b
c
c-Kit
C
ou
nt
sgSetd2.e5.1
sgRosa26
sgSetd2.e6.1
sgRosa26
sgSetd2.e8.1
sgRosa26
RPA3.e1.1
sgRNA:
Ren.38
SETD2.e6.1
SETD2.e8.1
SETD2.e8.2
SETD2.e8.3
Min Max
% GFP cells
NOMO-1-SpCas9
(MLL-AF9)
Days 211
THP-1-SpCas9
(MLL-AF9)
Days 211
MV4-11-SpCas9
(MLL-AF4)
Days 201
MOLM-13-SpCas9
(MLL-AF9)
Days 201
Fig. 6 The SETD2 SET domain is required for proliferation of MLL-leukemia cells. a Results of competitive proliferation assays shown as percentages of
mCherry+/GFP+ mouse MLL-AF9/NrasG12D-SpCas9 AML cells expressing indicated sgRNAs (top). Data from one representative experiment of two are
shown. Schematic representation of the domain structure of SETD2 (bottom). b Flow cytometric analysis of surface expression of c-Kit in MLL-AF9/
NrasG12D AML-SpCas9 cells upon CRISPR/Cas9-mediated mutagenesis of SETD2. c Heatmap representation of competitive proliferation assays shown as
the percentage of GFP-positive human AML cell lines stably expressing SpCas9 cells upon CRISPR/Cas9-mediated mutagenesis of the SETD2 SET domain
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04329-y
8 NATURE COMMUNICATIONS |  (2018) 9:1983 | DOI: 10.1038/s41467-018-04329-y | www.nature.com/naturecommunications
wanted to establish whether the methyltransferase activity of
SETD2 is necessary for the observed effects. Direction of SpCas9-
cleavage to functional protein domains was shown to greatly
increase the read-out in competitive proliferation assays48. We
employed CRISPR/Cas9-mediated mutagenesis of the enzymatic
SET domain to investigate whether catalytic activity of SETD2
was required for the oncogenicity of MLL-fusion proteins.
Introduction of three sgRNAs targeting the Setd2 SET domain in
SpCas9-expressing MLL-AF9/NrasG12D AML cells led to a
strong depletion of transduced cells over time, as shown before48
(Fig. 6a). Notably, CRISPR/Cas9-mediated mutagenesis of the
Setd2 SET domain was sufﬁcient to induce myeloid differentia-
tion of MLL-AF9/NrasG12D cells, as measured by down-
regulation of c-Kit together with upregulation of Mac-1 (Fig. 6b,
Supplementary Fig. 9a). In line, we found strong anti-proliferative
effects, induction of myeloid differentiation, and apoptosis upon
mutagenesis of the SETD2 SET domain in the human MLL-
rearranged AML cell lines MOLM-13 and MV4-11, THP-1, and
NOMO-1 (Fig. 6c; Supplementary Fig. 9b-f, Supplementary
Fig. 10).
These data show that the SET domain of SETD2 is required to
sustain the proliferative capacity and differentiation block of
MLL-fusion protein-expressing AML cells. In addition, these
results imply a functional involvement of the H3K36me3 mark in
the maintenance of MLL-fusion-dependent leukemia and offer a
plausible route for future pharmacological intervention.
Efﬁcient MLL-fusion-mediated transformation requires
SETD2. All our data show a strong functional requirement for
the expression and activity of SETD2 in the progression of MLL-
leukemia. As it is possible that alternative molecular mechanisms
pertain during initiation of MLL-rearranged leukemia, we tested
the involvement of SETD2 in this process. Setd2 knockdown
resulted in a signiﬁcant reduction in MLL-AF9-induced serial re-
plating capacity of mouse hematopoietic stem/progenitor cells
(HSPC), indicating that Setd2 expression is required to unleash
the full oncogenic potential of MLL-AF9 (Fig. 7a). Setd2 ablation
induced loss of compact colony morphology characteristic of
blast-like cells and induced the formation of large, dispersed
colonies reminiscent of mature myeloid clusters (Fig. 7b). Flow
cytometry conﬁrmed that Setd2-deﬁcient colonies expressed high
levels of the mature myeloid marker Mac-1 (Fig. 7c). To inves-
tigate the effect of SETD2 on oncogenic transformation in vivo,
we co-transduced fetal-liver-derived HSPC expressing a SpCas9
transgene49 with retroviral vectors encoding MLL-ENL and
Setd2-targeting or control sgRNAs. The contribution of cells
carrying sgRNA-induced mutations in the Setd2 SET domain to
leukemia development was investigated by ﬂow cytometric ana-
lysis of mCherry expression upon transplantation (Fig. 7d). While
cells expressing a control sgRNA showed robust contribution to
MLL-ENL-induced leukemia in vivo (56%), cells carrying Setd2-
mutations induced by two different sgRNAs were clearly under-
represented in the leukemic population (5–25%, Fig. 7e, f).
Thus, both downregulation and mutagenesis of SETD2 was
incompatible with efﬁcient oncogenic transformation by MLL-
fusion oncoproteins in vitro and in vivo. These results indicate
that SETD2 expression is required for leukemogenesis and
establish SETD2 as a novel actionable target in MLL-rearranged
leukemia.
SETD2 loss sensitizes MLL-AML cells to DOT1L inhibition.
Finally, we aimed to obtain insight into the molecular mechanism
that functionally connects SETD2 activity with MLL-fusion-
induced leukemia. ChIP-Rx showed that Setd2 downregulation
led to a concomitant reduction of both H3K36me3 and
H3K79me2 levels on MLL-target genes (Fig. 8a, b and Supple-
mentary Fig 11a), while it did not alter H3K4me3 density (Sup-
plementary Fig. 11b). As chromatin binding of MLL-fusion
proteins was shown to depend on H3K36me3 recognition via the
conserved interaction partner LEDGF9, we hypothesized that
reduction of H3K36me3 levels upon Setd2 loss might impair
chromatin binding of MLL-fusions. Indeed, knockdown of Setd2
caused reduced binding of MLL-AF9 to the promoters of the
canonical MLL-target genes Hoxa9 and Meis1 (Fig. 8c), leading to
reduced Hoxa9 expression (Fig. 8d).
Given the dependence of the dual H3K36me3-H3K79me2
signature across MLL-target genes on SETD2 and the strong
requirement of MLL-leukemia for the H3K79 methyltransferase
DOT1L21, we reasoned that SETD2 loss might cooperate with
pharmacologic inhibition of DOT1L. Treatment of mouse MLL-
AF9/NrasG12D and human MLL-AF4-expressing MV4-11 cells
with the clinical DOT1L inhibitor EPZ567650 potentiated the effects
of SETD2 downregulation, including growth inhibition, induction
of apoptosis, and onset of myeloid differentiation. Importantly,
none of these parameters were altered in SETD2-proﬁcient cells in
the presence of the same concentrations of the inhibitor (Fig. 8e, f,
Supplementary Fig. 11c-f). Finally, and consistent with a role of
DOT1L in DNA repair51, we found that combination of SETD2 loss
and DOT1L inhibition synergized in the induction of DNA damage
(Fig. 8g and Supplementary Fig. 11g).
These data show that loss of SETD2 expression in MLL-fusion
AML cells interferes with the H3K36me3-H3K79me2-signature
on MLL-target genes and impairs chromatin binding of MLL-
fusion proteins. In consequence, SETD2 loss led to hyper-
sensitization of MLL-leukemia cells to small-molecule-mediated
DOT1L inhibition, which provides a rationale for potential future
combination therapies in AML.
Discussion
Here, we provide the ﬁrst comprehensive protein–protein inter-
action network of MLL-fusion proteins in leukemia cells. We
show that functional annotation of conserved MLL-interaction
partners by loss-of-function screening enables the identiﬁcation
of conserved actionable nodes among the molecular network of
MLL-fusions. As exempliﬁed by our discovery of the histone
methyltransferase SETD2 as an essential factor in MLL-
rearranged leukemia, this approach can reveal novel genetic
dependencies and yield new entry points for targeting of the
entire group of MLL-rearranged leukemia, comprising over 75
different MLL-fusion partners.
Our results show that MLL-fusion proteins engage a large
number of distinct protein–protein interactions. This could be
explained by the modular nature of wild-type core MLL com-
plexes52,53 and by the speciﬁc architecture of their leukemic
counterparts4. Our analysis of protein–protein interactions of
selected, molecularly distinct MLL-fusion proteins greatly
expands the cellular catalog of MLL-interacting proteins. In
addition, it also provides novel insights into the topologies of
MLL-fusion proteins that transform cells via unknown mechan-
isms. For instance, interactome analysis of the MLL-GAS7-fusion
protein showed that it speciﬁcally interacts with components of
the CTLH complex, which is involved in microtubule dynamics
and chromosome segregation54.
A core set of 128 proteins constitutes the conserved inter-
actome of MLL-fusion proteins. In addition to known inter-
action partners of the wild-type MLL protein, such as MEN1,
DPY30, and LEDGF, it also contains several proteins whose
link to AML biology have only recently been established. For
instance, the protein SON interacts with MEN1 to regulate the
expression of leukemia-speciﬁc genes in a MLL-dependent
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manner55. Thus, functional annotation of the core network of
MLL-fusion interactors will contribute to establish novel links
between MLL-fusion proteins and important cellular processes
that had previously not been associated with the biology of
MLL-fusion proteins, such as mRNA splicing or protein
transport. Given the involvement of these molecular pathways
in basic cellular physiology, it is not surprising that more than
one third of proteins in the network of conserved MLL-fusion
protein interaction partners were identiﬁed as essential in
recent genome-wide screens39–42.
To discern MLL-fusion-associated genetic dependencies from
essential genes we employed a subtractive shRNA screening
approach. Strikingly, the gene encoding the methyltransferase
SETD2 was identiﬁed as an MLL-fusion-speciﬁc hit from this
screen with high conﬁdence. shRNA-mediated knockdown as
well as CRISPR/Cas9-induced mutagenesis of SETD2 caused
proliferation arrest and myeloid differentiation of MLL-fusion-
expressing primary and transformed human, and mouse AML
cells in vitro and in vivo. This is surprising, because SETD2 has
been implied to have tumor suppressor activity in various
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malignancies, including leukemia56–58. SETD2 knockdown was
reported to cause a driver-independent proliferative advantage of
leukemia cells in vitro and in vivo58. In contrast, another report
showed that mutational disruption of the SETD2 SET domain was
incompatible with MLL-AF9 AML cell growth48. Furthermore,
several genome-wide CRISPR/Cas9 screens identiﬁed SETD2 as
an essential gene in leukemia cell lines39–42. Finally, a recent
report showed that while homozygous Setd2 deletion in the
mouse strongly delayed leukemogenesis, heterozygous Setd2
deletion accelerated MLL-AF9-induced leukemia and caused
chemoresistance47. This is consistent with increased frequencies
of SETD2 mutations in high-risk leukemia patients that show
increased genomic complexity and chromothripsis57, and often
exhibit therapy resistance and relapse56. Therefore, as the
majority of cancer patients carry heterozygous SETD2 mutations,
SETD2 might act as a haplo-insufﬁcient tumor suppressor. In
contrast complete loss of SETD2 strongly impedes leukemia
development.
The most prominent cellular function of SETD2 is its non-
redundant H3K36 tri-methylation activity44. The H3K36me3
mark is enriched on gene bodies of actively transcribed genes59.
We found that MLL-target genes displayed high H3K36me3
levels, validating our proteomic identiﬁcation of SETD2 as an
interactor of MLL-fusion proteins at the genomic level. Given the
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large number of proteins harboring a H3K36me3-recognizing
PWWP motif60, several key cellular processes were postulated to
be inﬂuenced by this epigenetic mark, including transcriptional
elongation, splicing, and epigenetic control of gene expression61.
Consistent with a role for the PWWP motif of the MLL-interactor
LEDGF in chromatin binding of MLL-fusion proteins9, SETD2
loss caused reduced binding of MLL-AF9 to target promoters.
Thus, the interaction between SETD2 and MLL-fusion proteins
could be required to ensure efﬁcient chromatin binding of MLL-
fusions through the maintenance of high H3K36me3 levels on
MLL-target genes.
Our results clearly show that SETD2 is involved in the control
of the DNA damage response in MLL-fusion-expressing cells.
SETD2-deﬁcient cells exhibited high amounts of DNA damage
and increased γ-H2AX levels, even in the absence of exogenous
genotoxic stress. This is in line with a recent study showing that
SETD2 mutations in leukemia impair the DNA damage response,
thereby leading to chemotherapy resistance47. This defect is
attributed to loss of H3K36me3-dependent recruitment of repair
proteins to sites of DNA damage. It was shown that MLL-AF9-
transformed cells require an intact DNA damage response for full
oncogenicity, as experimental induction of DNA damage led to
differentiation of leukemia cells62. In line with this, down-
regulation of SETD2 was sufﬁcient to induce myeloid differ-
entiation of AML blasts. Therefore, a physical and functional
interaction between MLL-fusion proteins and SETD2 could be
required to guarantee efﬁcient, H3K36me3-dependent repair of
DNA lesions that continuously occur during MLL-fusion-induced
oncogenic transcription. However, given the accumulation of
DNA damage upon SETD2 loss, continuous SETD2 inhibition
might result in increased formation of chemoresistant AML
subclones.
We found that SETD2 was required for the maintenance of a
speciﬁc dual H3K36me3-H3K79me2 signature on target genes of
MLL-fusions. The H3K79me2 mark is catalyzed by the histone
methyltransferase DOT1L, which is critical for the establishment
and maintenance of MLL-rearranged leukemia21. SETD2 down-
regulation rendered MLL-fusion-expressing AML cells hyper-
sensitive to the pharmacological DOT1L-inhibitor EPZ5676
(Pinometostat), which is currently in clinical development. It will
be interesting to test whether this synergy can be exploited to
efﬁciently target chemoresistant AML cells that are carrying
SETD2 mutations.
In summary, our combined proteomic-functional genomic
analysis of MLL-fusion protein interactors enabled us to reveal
the molecular logic of how modular protein–protein interactions
can inﬂuence the oncogenicity of MLL-fusion proteins. Our
studies provide novel insights into the biology of MLL-fusion
proteins and identify an unexpected dependency of MLL-fusion-
expressing leukemia cells on the methyltransferase SETD2 during
leukemia initiation and maintenance, validating SETD2 as an
actionable target MLL-rearranged leukemia.
Methods
Constructs. MLL-fusion genes were assembled by fusing the cDNA of the MLL N-
terminus (amino acids 1-1396) to C-terminal parts of AF1p (EPS15), AF4 (AFF1),
AF9 (MLLT3), CBP (CREBBP), EEN (SH3GL1), ENL (MLLT1), and GAS7 (GAS7)
and cloned into pcDNA5/FRT/TO/SH/GW. Generation of the miR-E shRNA
vectors RT3GEN and RT3REN was previously described63,64. The SEM cell line
was infected with SGEN64. A pMSCV-MLL-AF9-IRES-Venus construct was used
for the in vitro re-plating assay, while a pMSCV-MLL-ENL-IRES-Luc2 construct
was used for the in vivo transformation assay. A V5-tagged version of the N-
terminal part of MLL (amino acids 1-1396) was cloned into a vector containing a
Doxycycline-inducible promoter. The C-terminal fragment of SETD2 (amino acids
950-2570) was cloned with a N-terminal 6×-Myc tag. The library of 768 shRNAs
was designed to target 128 conserved interaction partners of ≥5 selected MLL-
fusions with six shRNAs per gene. 97-mer oligomers (Integrated DNA Technol-
ogies) were reconstituted in H2O and stored at −80 °C. Mini-pools of six shRNAs
targeting the same candidate gene were ampliﬁed in parallel PCR reactions using
Pfx DNA polymerase (Invitrogen) as described64. Reactions were pooled and
puriﬁed using PCR Clean-up kit (Qiagen). PCR products were digested with EcoRI
and XhoI (New England Biolabs) and ligated with retro- or lentiviral vectors
allowing for inducible or constitutive shRNA expression together with selection
markers. After dialysis, ligations were introduced into Mega X DH10ß T1 electro-
competent cells (Invitrogen) by electroporation (2 kV, 200Ω, 25 µF) using a
MicroPulser Electroporator (Bio-Rad). The library was puriﬁed using Midi Prep
Kit (Qiagen). The presence of shRNA cassettes was veriﬁed by Sanger sequencing.
For CRISPR/Cas9-mediated mutagenesis, sgRNAs were cloned into lentiviral
vectors allowing for constitutive sgRNA expression together with GFP or mCherry
as previously described65. Sequences of sgRNAs used in the study are listed in
Supplementary Table 2.
Cell culture. All standard human leukemia cell lines such as: MOLM13, MV4-11,
HEL, HL-60, KYO-1, were obtained from DSMZ (Deutsche Sammlung von Mik-
roorganismen und Zellkulturen GmbH (DSMZ, www.dsmz.de)) or the American
Type Culture Collection (ATCC, www.atcc.org) and modiﬁed to express the eco-
tropic receptor and rtTA3. The murine Tet-On MLL-AF9/NrasG12D AML cell line
(RN2) was previously described66. All cell lines were cultured in RPMI 1640
(Gibco) supplemented with 10%FBS, 100 U/ml penicillin, and 100 µg/ml strepto-
mycin. Platinum-E cells were maintained in DMEM (Gibco) supplemented with
10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. SpCas9-expressing
variants of MOLM-13 and MLL-AF9/NrasG12D cells were generated by lentiviral
transduction followed by selection with Blasticidin (10 µg/ml). The SpCas9-
expressing subclone of MV4-11 was a gift from G. Winter (Dana Farber Cancer
Institute, Harvard University). The SpCas9-expressing THP-1 and NOMO-1 cell
lines were previously described67. MLL-AF9-FLAG cells were previously descri-
bed22. For proliferation curves, cells were seeded at low densities in triplicates and
cell numbers were determined using a multi-channel electronic cell counter
(CASY-I; Omni Life Science) in regular intervals. The DOT1L inhibitor EPZ5676
was obtained from BPS Bioscience. Human leukemic blast cells from heparinized
samples of AML patients (n= 3) were isolated on Ficoll-Hypaque gradients and
stored in liquid nitrogen. After thawing, cells were cultured in RPMI 1640 medium
containing 10% BIT 9500 Serum Substitute, 100 ng/ml SCF, 50 ng/ml Flt3L, 20 ng/
ml IL-3, 20 ng/ml G-CSF (all PeproTech), 10−4 M ß-mercaptoethanol, 50 µg/ml
gentamicin, and 10 µg/ml ciproﬂoxacin plus 500 nM SR1 and 1 µm UM72968. This
protocol typically leads to sustained proliferation of primary human AML cells
over 20 days, yielding a >10-fold expansion in vitro. All patients gave written
informed consent before blood or bone marrow was obtained. The study was
approved by the Institutional Review Board of the Medical University of Vienna.
Personal data from AML patients were used according to ethics approvals of
clinical partners for collection of clinical and genetic data upon informed consent.
All cell lines have been tested for mycoplasma contamination. Cell lines used in this
study were not listed in the database of commonly misidentiﬁed cell lines main-
tained by ICLAC.
Viral transduction. For retroviral transductions, Platinum-E cells were transiently
transfected with pGAG-POL and retroviral expression vectors using the calcium-
phosphate method in the presence of Chloroquine (25 µm, Sigma-Aldrich). Virus-
containing supernatant was harvested, ﬁltered (0.45 µm), and supplemented with
polybrene (5 µg/ml). Target cells were spinoculated at 1300×g for 90 min. For
lentiviral transductions, HEK293T cells were transiently transfected with psPAX2,
pMD2.G, and lentiviral expression vectors. Virus-containing supernatant was
harvested, ﬁltered (0.45 µm), and supplemented with polybrene (5 µg/ml). Target
cells were spinoculated at 1300×g for 90 min. Human primary AML cells were
transduced with concentrated lentiviral supernatants via centrifugation (1200×g,
90 min) at a multiplicity of infection of 20.
Generation of Flp-In cell lines. Jurkat Flp-In cells (Invitrogen) were transduced
with pLenti6/TR (Thermo) and a clone expressing high levels of the tetracycline
repressor (TR) was isolated. Cells were transfected with targeting constructs (in
pcDNA5/FRT/TO) together with pCAAGS-Flp-E by nucleofection using program
X-001 (Amaxa). Targeted cells were selected in Clonacell TCS medium (Stem Cell
Technologies) supplemented with 600 µg/ml Hygromycin B. Clones were isolated
and expanded in liquid medium in the presence of Hygromycin B. Expression of
MLL-fusions was tested by qRT-PCR after induction of transgene expression by
addition of 1 µg/ml Doxycycline for 24 h.
Afﬁnity puriﬁcation of protein complexes. Nuclear extracts from transgene-
expressing Jurkat cells were prepared and single-step STREP-Tactin puriﬁcations of
MLL-fusion proteins were performed as described33. All puriﬁcations of MLL-
fusion proteins were performed from 1 × 109 freshly harvested cells. After being
washed with PBS, cells were incubated in buffer N (300 mM sucrose, 10 mM
HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1 mM DTT, 0.75
mM spermidine, 0.15 mM spermine, 0.1% Nonidet P-40, 50 mM NaF, 1 mM
Na3VO4, protease inhibitors) for 5 min on ice. Nuclei were collected by cen-
trifugation (500×g for 5 min), and the supernatant was removed. The nuclear pellet
was washed with buffer N. For the extraction of nuclear proteins, nuclei were
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resuspended in buffer C420 (20 mM HEPES pH 7.9, 420 mM NaCl, 25% glycerol,
1 mM EDTA, 1 mM EGTA, 0.1 mM DTT, 50 mM NaF, 1 mM Na3VO4, protease
inhibitors), vortexed brieﬂy, and shaken vigorously for 30 min. After centrifugation
for 1 h at 100,000×g, the protein concentration of the soluble nuclear fraction was
measured by Bradford assay. Prior to puriﬁcation, all nuclear extracts were adjusted
to 2 mg/ml and 150 mM NaCl with HEPES buffer (20 mM HEPES, 50 mM NaF, 1
mM Na3VO4, protease inhibitors). 15 mg of nuclear extract were pre-treated with
benzonase (20 U/ml) and RNase A (50 ng/ml) for 15 min at 4 °C. Nonspeciﬁc
binding to the afﬁnity resin was blocked by the addition of avidin (1 µg/ml). 150 μl
StrepTactin sepharose (IBA) was added and lysates were incubated for 2 h at 4 °C
with agitation. Beads were washed 3 times with TNN-HS buffer (50 mM HEPES
pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 50 mM NaF, 1 mM Na3VO4,
and protease inhibitors). Bound proteins were eluted by the addition of 100 µl 2.5
mM Biotin (Alfa Aesar) in TNN-HS buffer. Samples were digested with trypsin and
processed for LC-MS/MS analysis.
Mass spectrometry. Analysis of afﬁnity puriﬁcation samples was performed as
described previously33,34. All afﬁnity puriﬁcations were analyzed on a hybrid linear
trap quadrupole (LTQ) Orbitrap Velos mass spectrometer (Thermo Fisher Scien-
tiﬁc) coupled to a 1200 series high-performance liquid chromatography system
(Agilent Technologies) via a nano-electrospray ion source using liquid junction
(Proxeon). Solvents for HPLC separation of peptides were as follows: solvent A
consisted of 0.4% formic acid in water, and solvent B consisted of 0.4% formic acid
in 70% methanol and 20% isopropanol. 8 μl of the tryptic peptide mixture were
automatically loaded onto a trap column (Zorbax 300SB-C18 5 µm, 5 × 0.3 mm,
Agilent Biotechnologies). After washing, peptides were eluted by back-ﬂushing
onto a 16-cm-fused silica analytical column with an inner diameter of 50 µm
packed with C18-reversed phase material (ReproSil-Pur 120 C18-AQ, 3 µm, Dr.
Maisch) with a 27-min gradient ranging from 3 to 30% solvent B, followed by a 25-
min gradient from 30 to 70% solvent B and, ﬁnally, a 7-min gradient from 70 to
100% solvent B at a constant ﬂow rate of 100 nl/min. Analyses were performed in a
data-dependent acquisition mode, and dynamic exclusion for selected ions was 60
s. A top 15 collision-induced dissociation (CID) method was used, and a single lock
mass at m/z 445.120024 (Si(CH3)2O)6 was employed. Maximal ion accumulation
time allowed in CID mode was 50 ms for MSn in the LTQ and 500 ms in the C-
trap. Automatic gain control was used to prevent overﬁlling of the ion traps and
was set to 5000 in MSn mode for the LTQ and 106 ions for a full FTMS scan. Intact
peptides were detected in the Orbitrap Velos at 60,000 resolution at m/z 400.
Protein identiﬁcation and network analysis. For protein identiﬁcation, raw MS
data ﬁles were converted into Mascot generic format (.mgf) ﬁles and searched
against the human SwissProt protein database (v. 2013.01) using the two search
engines Mascot (v2.3.02, MatrixScience, London, UK) and Phenyx (v2.6, GeneBio,
Geneva, Switzerland). Carbamidomethyl cysteine and oxidized methionine were set
as ﬁxed and variable modiﬁcations, respectively; one missed tryptic cleavage site
per peptide was permitted. The Mascot and Phenyx identiﬁcations were combined
and ﬁltered as described32 to provide <1% protein false discovery rate (FDR).
Known MS contaminants, such as trypsin and keratin were removed from the
results, and further analysis of proteins speciﬁcally binding to the baits was
achieved by ﬁtting the MS data to the generalized linear statistical model: log(data)
~ A0, j+ Ai, j+ αi+ βi, k, where A0, j is the logarithm of the baseline abundance of
the j-th prey protein (estimated from the control AP-MS experiments), Ai, j is the
speciﬁc enrichment of the j-th prey in the pulldowns of i-th bait, and αi and βi, k are
the normalization terms that model the abundance of background proteome in the
k-th replicate pulldown of i-th bait (to estimate αi, DDX5 and DDX17 proteins
were used, as these are known components of the nuclear proteome background
and were ubiquitously present in all AP-MS experiments). To improve the accu-
racy, the model was independently applied to three different types of MS data:
Protein spectral counts (the Poisson distribution was used to model the data) and
the sum of peptide scores from either Mascot or Phenyx search results, assuming
the log-normal distribution. Only peptides unique to the protein groups were used.
The inference of the model parameters was achieved using JAGS v.3.0. For each
type of MS data, the p-value for the hypothesis that Ai,j > 0 (i.e., that the j-th prey
binds speciﬁcally to the i-th bait) was calculated and then the three p-values were
combined into a single p-value using the Fisher method. All the identiﬁed bait-prey
pairs were ranked by the combined p-value. The 300 most signiﬁcant interactions
per bait were retained. This cutoff represents a compromise between ensuring high
statistical signiﬁcance of the included interactors, but also capturing sufﬁcient
diversity in the interactomes of the selected MLL-fusion proteins. The proteins
shared by at least ﬁve baits were selected for further analysis. Seven proteins were
manually removed as these were either frequently observed contaminants or were
not detected in human hematopoietic cell lines. The ﬁnal set was comprised of 128
proteins. The resulting network was extended by the known protein–protein
interactions, which were retrieved from three different datasets: (i) the set of non-
redundant complexes in CORUM69, from which binary protein–protein interac-
tions were extracted using the matrix model. (ii) The set of interactions described
in ref. 70, which combines data from several public repositories. (iii) The set of
interactions reported in ref. 71, integrating different data sets. After removing self-
interactions, the ﬁnal network consisted of 365 PPIs between 101 core MLL-fusion
interactors, while 27 other interactors identiﬁed by AP-MS remained connected
only to the MLL-fusion baits. The network was partitioned into distinct protein
communities by maximizing the modularity score of the network over all possible
partitions using the “cluster_optimal” function of the “igraph” package in R. Gene
ontology (GO) term enrichment analysis for each separate network community
was performed. Enrichment was computed with the topGO package from R, using
the default algorithm and the annotation ﬁle from geneontology.org (18 November
2015). All human proteins in UniProtKB/Swiss-Prot were used as the background
population. p-values were corrected for multiple testing using the
Benjamini–Hochberg procedure (FDR). Based on functional annotation similarity,
unconnected nodes were assigned to the most enriched GO terms in each com-
munity. Enrichment of protein complexes within the network of 960 MLL-fusion
-interactors was estimated by Fisher’s exact test. Before enrichment, CORUM core
complexes sharing >70% of the proteins were iteratively merged to reduce the
redundancy. All proteins present in at least one complex were used as the back-
ground population. p-values were corrected for multiple testing as explained above.
Protein interaction networks were visualized using Cytoscape and Gephi. Detailed
information about all 960 identiﬁed interactors of MLL-fusion proteins is provided
in Supplementary Data 1.
Negative selection RNAi screening. MOLM-13 cells transduced with mini-pools
of retroviral vectors for shRNA-mediated targeting of conserved MLL-interactors
(coupled to GFP) were mixed in a 50:50 ratio with cells expressing control shRNAs
(coupled to dsRed) and cultured in the presence of Doxycycline (1 µg/ml). Changes
in GFP/dsRed ratios were examined by ﬂow cytometry over time. Percentages of
GFP-positive cells were measured at each time point during the experiment and
normalized to initial measurement after 2 days of Dox treatment. Gene essentiality
was assessed based on recent large-scale datasets from genome-wide screens39–42.
Based on individual scores from single screens, we assigned scores of 1 (essential)
vs. 0 (non-essential) to each gene in our data set. Our combined essentiality score
reﬂects the sum of all essentiality information per gene from 18 different experi-
ments. Thus, a gene that is ubiquitously essential will obtain a score of 18, while a
ubiquitously non-essential gene will obtain a score of 0. A gene was called essential
if it scored in ≥10 of 18 cell lines. Sequences of shRNAs used for the RNAi screen
are listed in Supplementary Data 2 and Supplementary Table 3.
Chromatin immunoprecipitation (ChIP-Rx) and sequencing. MLL-AF9/
NrasG12D AML cells and Drosophila melanogaster S2 cells were separately cross-
linked with 10% formaldehyde and quenched with glycine (2.5 M). Pellets were
washed, pooled, and resuspended in SDS lysis buffer (1% SDS, 10 mM EDTA, 50
mM Tris-HCl, pH 8.0). Chromatin was sonicated to obtain fragments of 150 bp
using a Bioruptor sonicator (Diagenode). 0.5% Triton X-100 was added to the
samples to allow solubilization of the sheared DNA. Chromatin was incubated with
antibodies overnight (5 µg each). Antibody-bound material was enriched using
protein-G-coupled magnetic beads (Invitrogen), washed (50 mM Hepes-KOH, pH
7.4; 500 mM LiCl; 1 mM EDTA; 1% NP40 and 0,5% Na-Deoxycholate), and
released using elution buffer (50 mM Tris-HCl, pH 8.0; 10 mM EDTA and 1%
SDS) at 65 °C. DNA-protein crosslinks were reverted by incubating the samples
overnight at 65 °C in the presence of 0.2 M NaCl. The DNA was treated with
RNaseA (0.2 mg/ml) and proteinase K (0.2 mg/ml) and puriﬁed using PCR clean-
up kit (Qiagen). Chromatin immunoprecipitation of FLAG-tagged MLL-AF9 was
performed using the High Sensitivity ChIP Kit (Abcam, 185913) according to
the manufacturer’s instructions. Antibodies used were: anti-H3K4me3 (Abcam,
8580) anti-H3K36me3 (Abcam, 9050), anti-H3K79me2 (Abcam, 3594), anti-Flag
(Sigma, F1804). Sequencing libraries were prepared using NEBNext Ultra DNA
Library Prep Kit for Illumina (New England BioLabs) and sequenced on Illumina
HiSeq 4000 using 50 bp single-read chemistry.
Raw ChIP-seq reads were evaluated with FastQC (version 0.11.4). Quality-
ﬁltering and trimming was done with PRINSEQ-lite (version 0.20.4). Resulting
high-quality reads were simultaneously mapped against the Mus musculus
(GRCm38) and Drosophila melanogaster (dm6) reference genomes via BWA
(version 0.7.15). SAMtools (version 1.4) was used to split the alignments into
mouse and Drosophila reads. Read normalization via the Drosophila melanogaster
spike-in material was carried out with Deeptools (version 2.5.0.1) for each sample.
Proﬁle plots of histone marks were also generated with Deeptools (version 2.5.0.1).
For the comparison of H3K79me2 vs. H3K36me3 signal intensities on MLL-target
genes vs. non-MLL-targets, an equally sized set of randomly selected non-MLL-
target genes was chosen. MLL-target genes represent genes that were
downregulated upon MLL-AF9 withdrawal as measured by microarray analysis22.
IGV was used for manual inspection and visualization of data. For the analysis of
histone mark intensities in genes, mapped reads per gene were counted with
featureCounts (1.5.0), respective input counts subtracted, and normalized via
TMM using the edgeR package. The Pearson correlation coefﬁcient between
changes in respective histone marks over gene bodies after Setd2 knockdown was
calculated with the functions bigwigCompare, multiBigwigSummary, and
plotCorrelation of Deeptools.
RNA sequencing. RNA was isolated using RNeasy kit (Qiagen). The amount of
total RNA was quantiﬁed using the Qubit 2.0 Fluorometric Quantitation system
(Life Technologies) and the RNA integrity number was determined using the
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Experion Automated Electrophoresis System (Bio-Rad). RNA-seq libraries were
prepared with TruSeq Stranded mRNA LT sample preparation kit (Illumina) using
Sciclone and Zephyr liquid handling robotics (PerkinElmer). Sequencing libraries
were pooled, diluted, and sequenced on an Illumina HiSeq 3000 using 50 bp single-
read chemistry. Base calls provided by the Illumina Realtime Analysis software
were converted into BAM format using Illumina2bam and demultiplexed using
BamIndexDecoder (https://github.com/wtsi-npg/illumina2bam). Initial quality
control of raw sequencing reads was done with FastQC (version 0.11.4) followed by
pre-processing with PRINSEQ-lite (version 0.20.4). Resulting high-quality reads
were mapped via STAR72 (version 2.5.0b) against the mouse (GRCm38) reference
genome. After processing of the alignment results with SAMtools (0.1.19) counts
per gene were obtained by HTSeq73 (version 0.6.0). Normalization and differential
expression analysis between two samples was carried out with DESeq274. For the
visualization of gene expression and unsupervised hierarchical clustering of the
samples the rlog normalization in DESeq2 was applied. We used the R library
pheatmap for sample clustering (euclidian distance, complete linkage clustering)
and heatmap.2 from the gplots package to visualize differentially expressed genes
(Pearson correlation and ward.D clustering).
Real-time PCR analysis. Total RNA was isolated using RNeasy mini kit (Qiagen).
Reverse transcription was performed with RevertAid RT Kit (Thermo Scientiﬁc)
using 300 ng RNA. Quantitative PCR was performed using SensiMix SYBR Hi-
ROX kit (Bioline) on a RotorGene Q PCR machine (RG-600, Qiagen). Results were
analyzed using the 2-ddC(t) method. Sequences of primers used for qPCR are listed
in Supplementary Table 4.
FACS analysis. Cells were incubated in Fc block reagent (murine: Biolegend,14-
0161-85, clone93; human: Biolegend 422301) prior to incubation with the following
antibodies: anti-human CD36 (Biolegend, 336207, clone 5-271), Brilliant Violet
421 anti-mouse/human CD11b (Biolegend, 101235, clone M1/70), APC Rat anti-
Mouse CD117 (BD Pharmingen, 553356= cell, clone 2B8), anti-Mouse Ly-6G (Gr-
1) (Biolegend, 108411, clone RB6-8C5). Samples were measured on LSR Fortessa or
Canto II ﬂow cytometers (BD Biosciences) and analyzed using FlowJo software
(Tree Star).
Co-immunoprecipitation. HEK293 cells stably expressing pMSCV-rtTA3-IRES-
EcoR-PGK-Puro were transiently transfected with the indicated constructs using
the PEI transfection method. The expression of the N-terminal MLL-fragment was
induced with Doxycycline for 24 h (1 µg/ml, Sigma Aldrich). The Proteasome
inhibitor MG-132 (Sigma-Aldrich, 10 mM in DMSO), was added to the medium 2
h before cell harvest. Cells were harvested in IP-lysis buffer (50 mM Tris/HCl pH
7.5, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 5 mM EGTA) supplemented with
protease and phosphatase inhibitors. Protein concentrations were determined with
Bradford protein assay (Biorad) using γ-globulin (Biorad) as a standard. Subse-
quently, lysates were incubated with Anti-Myc-tag mAb-Magnetic Beads (Biome-
dica GmbH) for 1.5 h with continuous rotation at 4 °C. Beads were recovered by
centrifugation and washed in IP-buffer. Bound proteins were released by addition
of Lämmli-sample-buffer (Biorad) and boiling for 10 min at 95 °C before SDS-
PAGE analysis and immunoblotting.
Western blotting. Western blotting was performed according to standard
laboratory protocols. Antibodies used were: anti-H3K36me3 (Abcam, 9050;
1:1000), anti-H3 (Abcam, 1791; 1:5000), anti-HA (Covance, MMS-101P; 1:2000),
anti-H2AX (Millipore 05-636; 1:5000) anti-Tubulin (Abcam, 7291; 1:5000), anti-
RCC-1 (Santa Cruz, sc-55559; 1:2000), anti-p21 (Santa Cruz, sc-6246; 1:1000), anti-
GAPDH (Santa Cruz, sc-365062; 1:1000), anti-V5-tag (Cell Signaling, 13202;
1:2000), anti-Myc (Abcam, 9106; 1:10000). Secondary antibodies used were: goat
anti-mouse HRP (Jackson ImmunoResearch, 115-035-03 or Thermo Fisher Sci-
entiﬁc, 31430; 1:5000), goat anti-rabbit HRP (Jackson ImmunoResearch, 111-035-
003 or Thermo Fisher Scientiﬁc 31460; 1:5000). Uncropped scans of all blots are
shown in Supplementary Fig. 12.
Cytospin analysis. Cells were cytocentrifuged onto glass slides and stained with
Giemsa staining solution before microscopic analysis. Images were processed using
Adobe Photoshop (Adobe).
Comet assay. Cells were treated with Doxycycline (1 µg/ml) to induce shRNA
expression. shRen.713-expressing cells were treated with 150 µm H2O2 for 10 min.
4 × 104 cells were washed in PBS and mixed with 100 µl, 0.5% low melting agarose.
The cell suspension was deposited on pre-chilled frosted glass slides pre-coated
with 1% agarose. Slides were immersed in pre-chilled lysis buffer (2.5 M NaCl, 10
mM Tris-HCl, 100 mM Na2EDTA, 10% DMSO, and 1% Triton X; pH 10) for 1–2 h
and washed with cold H2O (3 times for 10 min). Slides were incubated in elec-
trophoresis buffer (55 mM NaOH, 1 mM EDTA, 1% DMSO; pH 12.8) for 45 min
followed by electrophoresis at 35 V for 40 min. Samples were neutralized in 400
mM Tris-HCl buffer pH 7.0 for 1 h and washed once with pre-chilled H2O before
staining with SYBR Gold. Comet tail moments, deﬁned as the average distance
migrated by the DNA multiplied by the fraction of DNA in the comet tail, were
scored using the CASP image-analysis software.
Transplantation experiments. 1 × 106 Murine MLL-AF9/NrasG12D cells were
injected into the tail-vein of sub-lethally (5.5 Gy) irradiated C57BL/6 Ly5.1 reci-
pient (n= 5). Disease progression was monitored by bioluminescence imaging.
Doxycycline (4 mg/ml) was supplied to the drinking water of mice to activate the
expression of shRNAs. E14.5 fetal liver cells from C57BL/6 Ly5.2 embryos with
heterozygous expression of the SpCas9 transgene49 were co-transduced with ret-
roviral vectors allowing for constitutive expression of MLL-ENL and Luciferase,
and sgRNAs coupled to mCherry. The efﬁciency of infection ranged between
5–11%. Transduced fetal liver cells were injected into the tail-vein of lethally
(2 × 5.5 Gy) irradiated C57BL/6 Ly5.1 recipient mice. Terminally sick animals were
sacriﬁced after 50–60 days, and bone marrow was isolated from femurs and tibia.
Animals suffering from obvious other symptoms than leukemia were excluded
from the analyses. During all animal experiments we adhered to the 3 R principles
(reduction, replacement, and reﬁnement). Animal numbers were determined by
the investigator using previous experience and based on judgement of pilot
experiments. In general, animal numbers were chosen to be as small as possible but
large enough to provide needed estimates for statistical tests, based on previous
experience. All animal experiments were performed according to ethical animal
license protocols approved by the authorities of the Austrian government. No
randomization was used in transplantation experiments. The investigator was not
blinded to the group allocation during the experiment and while assessing the
outcome.
Hematopoietic progenitor re-plating assay. Fetal liver cells were retrovirally co-
transduced with MLL-AF9 coupled to Venus and vectors allowing for constitutive
expression of shRNAs coupled to mCherry. Venus/mCherry double-positive cells
were isolated by FACS sorting and seeded in complete methylcellulose medium
(MethoCult M3434). Colonies were scored in 7-day intervals and 5 × 103 cells were
re-plated.
Apoptosis assays. Annexin V staining was performed according to the manu-
facturer’s protocol (Annexin V Apoptosis Detection Kit PE, Affymetrix,
eBioscience). The TUNEL assay was performed according to the manufacturer’s
instructions (ApoBrdU Red DNA Fragmentation Kit; BioVision (K404-60)). Cells
were analyzed by ﬂow cytometry.
Genotyping of cells with CRISPR/Cas9-induced mutations. Targeted regions
were ampliﬁed in a PCR reaction using LA Taq® DNA Polymerase
(TaKaRa RR002A). PCR products were puriﬁed (Qiagen) and analyzed by Sanger
sequencing. Chromatograms were analyzed with the TIDE tool (Tracking of Indels
by Decomposition, https://tide-calculator.nki.nl)75 to quantify nature and fre-
quency of generated indels.
Cell cycle analysis. Murine MLL-AF9/NRasG12D AML cells were cultured in the
presence of Doxycycline (1 µg/ml), harvested, ﬁxed in 70% Ethanol and stored at
−20 °C until further analysis. Cells were stained with PI staining solution and
examined by ﬂow cytometry.
Statistical analysis. Two-tailed Student’s t-tests were used for statistical analysis if
not stated otherwise.
Data availability. The mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE partner repository with the
dataset identiﬁer PXD009338. RNA-seq and ChIP-seq data was deposited into the
Gene Expression Omnibus (GEO). GEO accession GSE110521.
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